677 related articles for article (PubMed ID: 23598174)
21. The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer.
Faleiro I; Apolónio JD; Price AJ; De Mello RA; Roberto VP; Tabori U; Castelo-Branco P
Future Oncol; 2017 Oct; 13(23):2045-2051. PubMed ID: 29019414
[TBL] [Abstract][Full Text] [Related]
22.
Liu L; Liu C; Fotouhi O; Fan Y; Wang K; Xia C; Shi B; Zhang G; Wang K; Kong F; Larsson C; Hu S; Xu D
Oncologist; 2017 Oct; 22(10):1178-1188. PubMed ID: 28754720
[TBL] [Abstract][Full Text] [Related]
23. Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.
Lu B; Ma Y; Wu G; Tong X; Guo H; Liang A; Cong W; Liu C; Wang H; Wu M; Zhao J; Guo Y
Clin Cancer Res; 2008 Nov; 14(22):7405-12. PubMed ID: 19010857
[TBL] [Abstract][Full Text] [Related]
24. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.
Lee DD; Leão R; Komosa M; Gallo M; Zhang CH; Lipman T; Remke M; Heidari A; Nunes NM; Apolónio JD; Price AJ; De Mello RA; Dias JS; Huntsman D; Hermanns T; Wild PJ; Vanner R; Zadeh G; Karamchandani J; Das S; Taylor MD; Hawkins CE; Wasserman JD; Figueiredo A; Hamilton RJ; Minden MD; Wani K; Diplas B; Yan H; Aldape K; Akbari MR; Danesh A; Pugh TJ; Dirks PB; Castelo-Branco P; Tabori U
J Clin Invest; 2019 Jan; 129(1):223-229. PubMed ID: 30358567
[TBL] [Abstract][Full Text] [Related]
25. [Hypermethylation as a potential prognostic factor and a clue to a better understanding of the molecular pathogenesis of medulloblastoma--results of a genomewide methylation scan].
Frühwald MC; O'Dorisio MS; Smith L; Dai Z; Wright FA; Paulus W; Jürgens H; Plass C
Klin Padiatr; 2001; 213(4):197-203. PubMed ID: 11528554
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
27. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of protocadherin10 (PCDH10) promoter to predict the prognosis of gastric cancer.
Hou YC; Deng JY; Zhang RP; Xie XM; Cui JL; Wu WP; Hao XS; Liang H
Cancer Biomark; 2015; 15(5):567-73. PubMed ID: 26406945
[TBL] [Abstract][Full Text] [Related]
29. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
30. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
[TBL] [Abstract][Full Text] [Related]
31. Promoter hypermethylation of multiple genes in astrocytic gliomas.
Gonzalez-Gomez P; Bello MJ; Arjona D; Lomas J; Alonso ME; De Campos JM; Vaquero J; Isla A; Gutierrez M; Rey JA
Int J Oncol; 2003 Mar; 22(3):601-8. PubMed ID: 12579314
[TBL] [Abstract][Full Text] [Related]
32. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
[TBL] [Abstract][Full Text] [Related]
33. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.
Malley DS; Hamoudi RA; Kocialkowski S; Pearson DM; Collins VP; Ichimura K
Acta Neuropathol; 2011 May; 121(5):651-61. PubMed ID: 21287394
[TBL] [Abstract][Full Text] [Related]
34. Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer.
Lee S; Oh T; Chung H; Rha S; Kim C; Moon Y; Hoehn BD; Jeong D; Lee S; Kim N; Park C; Yoo M; An S
Int J Oncol; 2012 Mar; 40(3):889-98. PubMed ID: 22038115
[TBL] [Abstract][Full Text] [Related]
35. hTERT methylation and expression in gastric cancer.
Gigek CO; Leal MF; Silva PN; Lisboa LC; Lima EM; Calcagno DQ; Assumpção PP; Burbano RR; Smith Mde A
Biomarkers; 2009 Dec; 14(8):630-6. PubMed ID: 20001710
[TBL] [Abstract][Full Text] [Related]
36. Hypomethylated CpG around the transcription start site enables TERT expression and HPV16 E6 regulates TERT methylation in cervical cancer cells.
Jiang J; Zhao LJ; Zhao C; Zhang G; Zhao Y; Li JR; Li XP; Wei LH
Gynecol Oncol; 2012 Mar; 124(3):534-41. PubMed ID: 22108635
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer.
Gu S; Lin S; Ye D; Qian S; Jiang D; Zhang X; Li Q; Yang J; Ying X; Li Z; Tang M; Wang J; Jin M; Chen K
Clin Epigenetics; 2019 Mar; 11(1):41. PubMed ID: 30846004
[TBL] [Abstract][Full Text] [Related]
38. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
39. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
Waszak SM; Northcott PA; Buchhalter I; Robinson GW; Sutter C; Groebner S; Grund KB; Brugières L; Jones DTW; Pajtler KW; Morrissy AS; Kool M; Sturm D; Chavez L; Ernst A; Brabetz S; Hain M; Zichner T; Segura-Wang M; Weischenfeldt J; Rausch T; Mardin BR; Zhou X; Baciu C; Lawerenz C; Chan JA; Varlet P; Guerrini-Rousseau L; Fults DW; Grajkowska W; Hauser P; Jabado N; Ra YS; Zitterbart K; Shringarpure SS; De La Vega FM; Bustamante CD; Ng HK; Perry A; MacDonald TJ; Hernáiz Driever P; Bendel AE; Bowers DC; McCowage G; Chintagumpala MM; Cohn R; Hassall T; Fleischhack G; Eggen T; Wesenberg F; Feychting M; Lannering B; Schüz J; Johansen C; Andersen TV; Röösli M; Kuehni CE; Grotzer M; Kjaerheim K; Monoranu CM; Archer TC; Duke E; Pomeroy SL; Shelagh R; Frank S; Sumerauer D; Scheurlen W; Ryzhova MV; Milde T; Kratz CP; Samuel D; Zhang J; Solomon DA; Marra M; Eils R; Bartram CR; von Hoff K; Rutkowski S; Ramaswamy V; Gilbertson RJ; Korshunov A; Taylor MD; Lichter P; Malkin D; Gajjar A; Korbel JO; Pfister SM
Lancet Oncol; 2018 Jun; 19(6):785-798. PubMed ID: 29753700
[TBL] [Abstract][Full Text] [Related]
40. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]